An Open-Label, Multiple Dose, Safety and Pharmacokinetic Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2015
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Zogenix
- 30 Sep 2015 Top-line pharmacokinetics results announced in Zogenix media release.
- 17 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Mar 2015 Dosing of patients has been initiated, according to a Zogenix media release.